CN Patent

CN110903337A — 用于调节生长激素受体表达的组合物和方法

Assigned to Ionis Pharmaceuticals Inc · Expires 2020-03-24 · 6y expired

What this patent protects

本实施方案提供使用靶向生长激素受体(GHR)的反义化合物或寡核苷酸用于治疗、预防或减轻与过量生长激素相关的疾病的方法、化合物以及组合物。

USPTO Abstract

本实施方案提供使用靶向生长激素受体(GHR)的反义化合物或寡核苷酸用于治疗、预防或减轻与过量生长激素相关的疾病的方法、化合物以及组合物。

Drugs covered by this patent

Patent Metadata

Patent number
CN110903337A
Jurisdiction
CN
Classification
—
Expires
2020-03-24
Drug substance claim
No
Drug product claim
No
Assignee
Ionis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.